Farma

MiniMe
BGBIO 06.03.2021 kl 09:48 5109

Fortjener egen tråd!

https://newsweb.oslobors.no/message/526986


BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)

Bergen, Norway, 6 March 2021?- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today delivered a Science Spotlight oral presentation
on preclinical COVID-19 data at the annual Conference on Retroviruses and
Opportunistic Infections (CROI), taking place from 6-10 March 2021.

The presentation was led by BerGenBio's collaborator, Professor Wendy Maury,
Professor of Microbiology and Immunology at the University of Iowa (Iowa City,
USA), who presented data showing that AXL enhances the ability of SARS-CoV-2 to
infect cell lines from the human airway, increasing the amount of virus measured
in those cells. Treating the human cell lines, Vero E6 and human ACE2-expressing
A549 lung cancer cell lines, with the AXL kinase inhibitor, bemcentinib reduces
the amount of SARS-CoV-2 virus infecting these cells, and it does this by
reducing ACE2-mediated viral cell entry by endocytosis, rather than at the cell
surface.

Additionally an in vivo study also measured the effect of bemcentinib to treat a
type of coronavirus which naturally infects mice - murine hepatitis virus (MHV).
In this study, not only was bemcentinib found to significantly inhibit the viral
load of MHV found in the liver of these animals, but it also significantly
enhanced signatures of a type I IFN response, a potent mediator of the innate
antiviral response.

In conclusion, the effect of bemcentinib demonstrated potent antiviral effects
in preclinical SARS-CoV-2 and other coronavirus models. Further, the findings
support BerGenBio's ongoing Phase II trial evaluating bemcentinib for the
treatment of hospitalised COVID-19 patients in South Africa and India.

The presentation will be made available on BerGenBio's website under
'Presentations'.

Full details of the presentation are as follows:

Title: Targeting the receptor AXL by bemcentinib prevents SARS-CoV-2 infection

Author: Professor Wendy Maury, Professor of Microbiology and Immunology at the
University of Iowa (Iowa City, USA)

Abstract No. 2672

-Ends-



Redigert 06.03.2021 kl 09:54

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.